IMNR to halt Remune trial

Immune Response (IMNR) said it will not continue a Phase III study of Remune started by former partner Agouron Pharmaceuticals. Agouron,

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE